9ZT1 Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Alzamend Neuro, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$10.92 |
| 52 Week Low | US$2.16 |
| Beta | -0.15 |
| 1 Month Change | 0% |
| 3 Month Change | -6.80% |
| 1 Year Change | -76.52% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9ZT1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | 1.2% |
| 1Y | -76.5% | -13.3% | 14.0% |
Return vs Industry: 9ZT1 underperformed the German Biotechs industry which returned -27.9% over the past year.
Return vs Market: 9ZT1 underperformed the German Market which returned 0.1% over the past year.
Price Volatility
| 9ZT1 volatility | |
|---|---|
| 9ZT1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 9ZT1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 9ZT1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 6 | Stephan Jackman | www.alzamend.com |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc. Fundamentals Summary
| 9ZT1 fundamental statistics | |
|---|---|
| Market cap | €4.93m |
| Earnings (TTM) | -€13.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 9ZT1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9ZT1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.16m |
| Earnings | -US$15.16m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9ZT1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/27 17:52 |
| End of Day Share Price | 2023/10/30 00:00 |
| Earnings | 2023/10/31 |
| Annual Earnings | 2023/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alzamend Neuro, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Michael Okunewitch | Maxim Group |